Manel Saidani

Head of Marketing & Analytics & International Partner Markets Biogen

Pharma Launch Excellence Summit Main Conference Day 1: Wednesday 2nd December

2:00 PM Panel Discussion: Leveraging Medical Affairs to Build Evidence, Engage Stakeholders, & Accelerate Launch Success

Medical affairs has evolved from a launch support function into a key driver of launch success. With long-term launch performance often determined within the first six months post-launch, medical affairs teams can be utilised to gather evidence early, effectively engage stakeholders and ensure that appropriate healthcare systems are ready to adopt a new product at launch.

• Learning why engaging the medical affairs function 48–60 months before launch is critical to drive launch success

• Hearing how to effectively leverage medical affairs teams to lead evidence generation when preparing for launch execution

• Using the medical affairs function to prepare healthcare systems for rapid adoption of therapies at launch: What steps can you take?

Pharma Launch Excellence Summit Pre-Conference Focus Day: Launch Excellence in Rare Disease: Tuesday 1st December

10:00 AM Case Study Presentation: Launching Rare Disease Products Through Uncertainty: Lessons from Neuromuscular Rare Disease Launches in Partner Markets

Launching a rare disease therapy requires navigating significant uncertainty, from evolving regulatory pathways and limited disease awareness to fragmented patient populations and changing operational realities. Success depends not only on launch planning but on the ability to continuously adapt while maintaining focus on patient impact.

Drawing on launch experiences across ALS, Friedreich's Ataxia (FA), and Spinal Muscular Atrophy (SMA), this session will share practical lessons on building resilient launch strategies, strengthening internal alignment, and addressing market-specific challenges to maximise patient access and commercial success.

• Conducting effective opportunity assessment and outlining the unique risks associated with rare disease launches and the corresponding agile strategy

• Building a compelling business cases to advocate for different opportunities and addressing the unmet needs of rare disease patients while minimising business complexity

• Developing an agile GTM to adapt to local uncertainties and navigate complex ecosystems and patient journeys

• Overcoming internal operational challenges while adapting global processes to meet diverse local market needs during launch

• Leveraging various access mechanisms to accelerate treatment availability and address unmet needs as early as possible: Drawing conclusions from HCP and Authorities engagement in very different territories (Turkey, Algeria, Greece, Balkans)

• Accelerating speed of referral and diagnosis while adapting to local ecosystems from the most centralised to the most decentralised ones

Check out the incredible speaker line-up to see who will be joining Manel.

Download The Latest Agenda

In Partnership With:

QUESTIONS?

Address: IQPC Ltd, 129 Wilton Road,
London SW1V 1JZ
Telephone: 44 (0) 207 368 9300
Fax: 44 (0) 207 368 9301
Email: enquire@iqpc.co.uk